NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$5.6b

Last Updated

2021/04/10 23:16 UTC

Data Sources

Company Financials +

Executive Summary

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Vir Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VIR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: VIR's weekly volatility has increased from 19% to 31% over the past year.


Market Performance


7 Day Return

-13.0%

VIR

-2.2%

US Biotechs

2.1%

US Market


1 Year Return

46.2%

VIR

31.5%

US Biotechs

56.3%

US Market

Return vs Industry: VIR exceeded the US Biotechs industry which returned 31.3% over the past year.

Return vs Market: VIR underperformed the US Market which returned 55.3% over the past year.


Shareholder returns

VIRIndustryMarket
7 Day-13.0%-2.2%2.1%
30 Day-30.2%-4.2%2.4%
90 Day55.0%-5.5%6.1%
1 Year46.2%46.2%33.6%31.5%59.1%56.3%
3 Yearn/a26.9%21.1%65.7%55.1%
5 Yearn/a40.2%29.9%122.3%97.6%

Long-Term Price Volatility Vs. Market

How volatile is Vir Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vir Biotechnology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VIR ($43.13) is trading below our estimate of fair value ($188.9)

Significantly Below Fair Value: VIR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VIR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: VIR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VIR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VIR is overvalued based on its PB Ratio (7.7x) compared to the US Biotechs industry average (3.9x).


Future Growth

How is Vir Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

47.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VIR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VIR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VIR's revenue (6.2% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: VIR's revenue (6.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VIR is forecast to be unprofitable in 3 years.


Past Performance

How has Vir Biotechnology performed over the past 5 years?

-70.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: VIR is currently unprofitable.

Growing Profit Margin: VIR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if VIR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare VIR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: VIR has a negative Return on Equity (-41.66%), as it is currently unprofitable.


Financial Health

How is Vir Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: VIR's short term assets ($772.4M) exceed its short term liabilities ($99.1M).

Long Term Liabilities: VIR's short term assets ($772.4M) exceed its long term liabilities ($102.8M).


Debt to Equity History and Analysis

Debt Level: VIR is debt free.

Reducing Debt: VIR had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VIR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if VIR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Vir Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

George Scangos (72 yo)

4.25yrs

Tenure

US$3,944,607

Compensation

Dr. George A. Scangos, Ph.D., serves as the Chief Executive Officer, President and Director of Vir Biotechnology, Inc. since January 2017. Dr. Scangos served as the Chief Executive Officer of Biogen Idec L...


CEO Compensation Analysis

Compensation vs Market: George's total compensation ($USD3.94M) is below average for companies of similar size in the US market ($USD6.40M).

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: VIR's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: VIR's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.3%.


Top Shareholders

Company Information

Vir Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vir Biotechnology, Inc.
  • Ticker: VIR
  • Exchange: NasdaqGS
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.603b
  • Shares outstanding: 129.91m
  • Website: https://www.vir.bio

Number of Employees


Location

  • Vir Biotechnology, Inc.
  • 499 Illinois Street
  • Suite 500
  • San Francisco
  • California
  • 94158
  • United States

Listings


Biography

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatiti...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/10 23:16
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.